Inhibition of O-GlcNAc transferase activity reprograms prostate cancer cell metabolism

Oncotarget

Volumn 7, Issue 11, 2016, Pages 12464-12476

  Itkonen, Harri M ^a,b   Gorad, Saurabh S ^c,d   Duveau, Damien Y ^e   Martin, Sara E S ^f   Barkovskaya, Anna ^b,c   Bathen, Tone F ^c   Moestue, Siver A ^c,d   Mills, Ian G ^a,b,g  

^a UNIVERSITY OF OSLO   (Norway)

^b OSLO UNIVERSITY HOSPITAL   (Norway)

^c NORWEGIAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Norway)

^d TRONDHEIM UNIVERSITY HOSPITAL   (Norway)

^e NATIONAL INSTITUTES OF HEALTH   (United States)

^f HARVARD INSTITUTES OF MEDICINE   (United States)

^g QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

Author keywords

Androgen receptor; Glycosylation; Metabolism; O glcnac transferase; Prostate cancer

Indexed keywords

ALANINE AMINOTRANSFERASE; CYCLOSERINE; ENZYME INHIBITOR; LACTIC ACID; METFORMIN; O N ACETYL D GLUCOSAMINE TRANSFERASE; ROTENONE; ST 045849; TRANSFERASE; UNCLASSIFIED DRUG; ANDROGEN RECEPTOR; AR PROTEIN, HUMAN; N ACETYLGLUCOSAMINYLTRANSFERASE; O-GLCNAC TRANSFERASE;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CANCER RECURRENCE; CELL DEATH; CELL METABOLISM; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; DRUG TARGETING; ENZYME ACTIVITY; ENZYME INHIBITION; GENE EXPRESSION REGULATION; GLUCOSE INTAKE; GLYCOLYSIS; GROWTH RATE; HUMAN; HUMAN CELL; MALE; NUCLEAR REPROGRAMMING; OXIDATIVE PHOSPHORYLATION; PREDICTION; PROSTATE CANCER; PROSTATE CANCER CELL LINE; PROSTATE EPITHELIUM; PROTEIN TARGETING; UPREGULATION; ANTAGONISTS AND INHIBITORS; DRUG EFFECTS; GLYCOSYLATION; METABOLISM; PATHOLOGY; PROSTATE TUMOR; TUMOR CELL LINE;

CELL LINE, TUMOR; CELL PROLIFERATION; ENZYME INHIBITORS; GLYCOSYLATION; HUMANS; MALE; N-ACETYLGLUCOSAMINYLTRANSFERASES; PROSTATIC NEOPLASMS; RECEPTORS, ANDROGEN;

EID: 84962834041     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.7039     Document Type: Article

References (46)

1. Barfeld SJ, Itkonen HM, Urbanucci A and Mills IG. Androgen-regulated metabolism and biosynthesis in prostate cancer. Endocrine-related cancer. 2014; 21:T57-66.
2. Itkonen HM, Engedal N, Babaie E, Luhr M, Guldvik IJ, Minner S, Hohloch J, Tsourlakis MC, Schlomm T and Mills IG. UAP1 is overexpressed in prostate cancer and is protective against inhibitors of N-linked glycosylation. Oncogene. 2014.
3. Massie CE, Lynch A, Ramos-Montoya A, Boren J, Stark R, Fazli L, Warren A, Scott H, Madhu B, Sharma N, Bon H, Zecchini V, Smith DM, Denicola GM, Mathews N, Osborne M, et al. The androgen receptor fuels prostate cancer by regulating central metabolism and biosynthesis. The EMBO journal. 2011; 30:2719-2733.
4. Heemers H, Vanderhoydonc F, Roskams T, Shechter I, Heyns W, Verhoeven G and Swinnen JV. Androgens stimulate coordinated lipogenic gene expression in normal target tissues in vivo. Molecular and cellular endocrinology. 2003; 205:21-31.
5. Cantor JR and Sabatini DM. Cancer cell metabolism: one hallmark, many faces. Cancer discovery. 2012; 2:881-898.
6. Preston MA, Riis AH, Ehrenstein V, Breau RH, Batista JL, Olumi AF, Mucci LA, Adami HO and Sorensen HT. Metformin Use and Prostate Cancer Risk. European urology. 2014.
7. Ross SJ and Critchlow SE. Emerging approaches to target tumor metabolism. Current opinion in pharmacology. 2014; 17C:22-29.
8. Jia J, Zhu F, Ma X, Cao Z, Li Y and Chen YZ. Mechanisms of drug combinations: interaction and network perspectives. Nature reviews Drug discovery. 2009; 8:111-128.
9. Metallo CM and Vander Heiden MG. Metabolism strikes back: metabolic flux regulates cell signaling. Genes & development. 2010; 24:2717-2722.
10. Hanover JA, Krause MW and Love DC. Bittersweet memories: linking metabolism to epigenetics through O-GlcNAcylation. Nature reviews Molecular cell biology. 2012; 13:312-321.
11. Vaidyanathan K, Durning S and Wells L. Functional O-GlcNAc modifications: implications in molecular regulation and pathophysiology. Critical reviews in biochemistry and molecular biology. 2014; 49:140-163.
12. Yi W, Clark PM, Mason DE, Keenan MC, Hill C, Goddard WA, 3rd, Peters EC, Driggers EM and Hsieh-Wilson LC. Phosphofructokinase 1 glycosylation regulates cell growth and metabolism. Science. 2012; 337:975-980.
13. Jang H, Kim TW, Yoon S, Choi SY, Kang TW, Kim SY, Kwon YW, Cho EJ and Youn HD. O-GlcNAc regulates pluripotency and reprogramming by directly acting on core components of the pluripotency network. Cell stem cell. 2012; 11:62-74.
14. Ranuncolo SM, Ghosh S, Hanover JA, Hart GW and Lewis BA. Evidence of the involvement of O-GlcNAc-modified human RNA polymerase II CTD in transcription in vitro and in vivo. The Journal of biological chemistry. 2012; 287:23549-23561.
15. Rozanski W, Krzeslak A, Forma E, Brys M, Blewniewski M, Wozniak P and Lipinski M. Prediction of bladder cancer based on urinary content of MGEA5 and OGT mRNA level. Clinical laboratory. 2012; 58:579-583.
16. Mi W, Gu Y, Han C, Liu H, Fan Q, Zhang X, Cong Q and Yu W. O-GlcNAcylation is a novel regulator of lung and colon cancer malignancy. Biochimica et biophysica acta. 2011; 1812:514-519.
17. Itkonen HM, Minner S, Guldvik IJ, Sandmann MJ, Tsourlakis MC, Berge V, Svindland A, Schlomm T and Mills IG. O-GlcNAc transferase integrates metabolic pathways to regulate the stability of c-MYC in human prostate cancer cells. Cancer research. 2013; 73:5277-5287.
18. Gross BJ, Kraybill BC and Walker S. Discovery of O-GlcNAc transferase inhibitors. Journal of the American Chemical Society. 2005; 127:14588-14589.
19. Ortiz-Meoz RF, Jiang J, Lazarus MB, Orman M, Janetzko J, Fan C, Duveau DY, Tan ZW, Thomas CJ and Walker S. A small molecule that inhibits OGT activity in cells. ACS chemical biology. 2015; 10:1392-1397.
20. Caldwell SA, Jackson SR, Shahriari KS, Lynch TP, Sethi G, Walker S, Vosseller K and Reginato MJ. Nutrient sensor O-GlcNAc transferase regulates breast cancer tumorigenesis through targeting of the oncogenic transcription factor FoxM1. Oncogene. 2010; 29:2831-2842.
21. Lynch TP, Ferrer CM, Jackson SR, Shahriari KS, Vosseller K and Reginato MJ. Critical role of O-Linked beta-N-acetylglucosamine transferase in prostate cancer invasion, angiogenesis, and metastasis. The Journal of biological chemistry. 2012; 287:11070-11081.
22. Kazemi Z, Chang H, Haserodt S, McKen C and Zachara NE. O-linked beta-N-acetylglucosamine (O-GlcNAc) regulates stress-induced heat shock protein expression in a GSK-3beta-dependent manner. The Journal of biological chemistry. 2010; 285:39096-39107.
23. Chen S, Xu Y, Yuan X, Bubley GJ and Balk SP. Androgen receptor phosphorylation and stabilization in prostate cancer by cyclin-dependent kinase 1. Proceedings of the National Academy of Sciences of the United States of America. 2006; 103:15969-15974.
24. Malumbres M. Cyclin-dependent kinases. Genome Biol. 2014; 15:122.
25. Taylor BS, Schultz N, Hieronymus H, Gopalan A, Xiao Y, Carver BS, Arora VK, Kaushik P, Cerami E, Reva B, Antipin Y, Mitsiades N, Landers T, Dolgalev I, Major JE, Wilson M, et al. Integrative genomic profiling of human prostate cancer. Cancer Cell. 2010; 18:11-22.
26. Barrientos A and Moraes CT. Titrating the effects of mitochondrial complex I impairment in the cell physiology. The Journal of biological chemistry. 1999; 274:16188-16197.
27. Viollet B, Guigas B, Sanz Garcia N, Leclerc J, Foretz M and Andreelli F. Cellular and molecular mechanisms of metformin: an overview. Clinical science. 2012; 122:253-270.
28. Adeva-Andany M, Lopez-Ojen M, Funcasta-Calderon R, Ameneiros-Rodriguez E, Donapetry-Garcia C, Vila-Altesor M and Rodriguez-Seijas J. Comprehensive review on lactate metabolism in human health. Mitochondrion. 2014; 17C:76-100.
29. Chou TY, Hart GW and Dang CV. c-Myc is glycosylated at threonine 58, a known phosphorylation site and a mutational hot spot in lymphomas. The Journal of biological chemistry. 1995; 270:18961-18965.
30. Bond MR and Hanover JA. A little sugar goes a long way: the cell biology of O-GlcNAc. The Journal of cell biology. 2015; 208:869-880.
31. Zhu Y, Liu TW, Madden Z, Yuzwa SA, Murray K, Cecioni S, Zachara N and Vocadlo DJ. Post-translational O-GlcNAcylation is essential for nuclear pore integrity and maintenance of the pore selectivity filter. Journal of molecular cell biology. 2015.
32. Mizuguchi-Hata C, Ogawa Y, Oka M and Yoneda Y. Quantitative regulation of nuclear pore complex proteins by O-GlcNAcylation. Biochimica et biophysica acta. 2013; 1833:2682-2689.
33. Laoukili J, Alvarez M, Meijer LA, Stahl M, Mohammed S, Kleij L, Heck AJ and Medema RH. Activation of FoxM1 during G2 requires cyclin A/Cdk-dependent relief of autorepression by the FoxM1 N-terminal domain. Molecular and cellular biology. 2008; 28:3076-3087.
34. Costa RH. FoxM1 dances with mitosis. Nature cell biology. 2005; 7:108-110.
35. Lazarus MB, Jiang J, Kapuria V, Bhuiyan T, Janetzko J, Zandberg WF, Vocadlo DJ, Herr W and Walker S. HCF-1 is cleaved in the active site of O-GlcNAc transferase. Science. 2013; 342:1235-1239.
36. Zhong J, Martinez M, Sengupta S, Lee A, Wu X, Chaerkady R, Chatterjee A, O'Meally RN, Cole RN, Pandey A and Zachara NE. Quantitative phosphoproteomics reveals crosstalk between phosphorylation and O-GlcNAc in the DNA damage response pathway. Proteomics. 2015; 15:591-607.
37. Vaz CV, Alves MG, Marques R, Moreira PI, Oliveira PF, Maia CJ and Socorro S. Androgen-responsive and nonresponsive prostate cancer cells present a distinct glycolytic metabolism profile. The international journal of biochemistry & cell biology. 2012; 44:2077-2084.
38. Tessem MB, Swanson MG, Keshari KR, Albers MJ, Joun D, Tabatabai ZL, Simko JP, Shinohara K, Nelson SJ, Vigneron DB, Gribbestad IS and Kurhanewicz J. Evaluation of lactate and alanine as metabolic biomarkers of prostate cancer using 1H HR-MAS spectroscopy of biopsy tissues. Magnetic resonance in medicine : official journal of the Society of Magnetic Resonance in Medicine / Society of Magnetic Resonance in Medicine. 2008; 60:510-516.
39. Nelson SJ, Kurhanewicz J, Vigneron DB, Larson PE, Harzstark AL, Ferrone M, van Criekinge M, Chang JW, Bok R, Park I, Reed G, Carvajal L, Small EJ, Munster P, Weinberg VK, Ardenkjaer-Larsen JH, et al. Metabolic imaging of patients with prostate cancer using hyperpolarized [1-(1)(3)C]pyruvate. Science translational medicine. 2013; 5:198ra108.
40. Beuster G, Zarse K, Kaleta C, Thierbach R, Kiehntopf M, Steinberg P, Schuster S and Ristow M. Inhibition of alanine aminotransferase in silico and in vivo promotes mitochondrial metabolism to impair malignant growth. The Journal of biological chemistry. 2011; 286:22323-22330.
41. Caminero JA, Sotgiu G, Zumla A and Migliori GB. Best drug treatment for multidrug-resistant and extensively drug-resistant tuberculosis. The Lancet Infectious diseases. 2010; 10:621-629.
42. Musana KA, Yale SH and Abdulkarim AS. Tests of liver injury. Clinical medicine & research. 2004; 2:129-131.
43. Hart GW. Three Decades of Research on O-GlcNAcylation - A Major Nutrient Sensor That Regulates Signaling, Transcription and Cellular Metabolism. Frontiers in endocrinology. 2014; 5:183.
44. Austdal M, Skrastad RB, Gundersen AS, Austgulen R, Iversen AC and Bathen TF. Metabolomic biomarkers in serum and urine in women with preeclampsia. PloS one. 2014; 9:e91923.
45. Sitter B, Bathen TF, Tessem M-B and Gribbestad IS. High-resolution magic angle spinning (HR MAS) MR spectroscopy in metabolic characterization of human cancer. Progress in Nuclear Magnetic Resonance Spectroscopy. 2009; 54:239-254.
46. Wider G and Dreier L. Measuring protein concentrations by NMR spectroscopy. Journal of the American Chemical Society. 2006; 128:2571-2576.